Talk:Alemtuzumab

I think this article is vandalised once. It has no gangsters, and the diff is shown here: [1] --BlakeCS 23:32, 24 February 2007 (UTC)Reply

doi:10.1111/j.1365-2141.2007.06687.x - can cause sarcoid! JFW | T@lk 22:44, 23 June 2007 (UTC)Reply

http://news.bbc.co.uk/2/hi/health/7680641.stm —Preceding unsigned comment added by 78.24.121.60 (talk) 06:09, 23 October 2008 (UTC)Reply

Have used this to replace dead yahoo URL. - Rod57 (talk) 09:41, 25 October 2011 (UTC)Reply

Campath is currently being trialed by cambridge university to treat MS. —Preceding unsigned comment added by 60.241.168.49 (talk) 05:07, 27 May 2009 (UTC)Reply

This is mentioned twice, we really need to remove one. Any preference which should go? (I'd say the second mention, so the relicense is under the controversy). Unless anyone has any strong feeling either way I'll update Jtowler (talk) 07:21, 20 March 2013 (UTC)Reply

per a, shall we politely say, obsessive website [a]:

"Take the case of Sanofi's Lemtrada, a drug to treat multiple sclerosis that has been approved all over the world. Taken once a year, it alleviates the symptoms of the disease and delays the onset of paralysis. Although the drug has already been approved to treat leukemia-so it is safe-FDA did not approve the design of its Phase III study and refused to approve it last December. Sanofi resubmitted the drug with additional data in May, but no word yet from the FDA."

[a] http://www.realclearmarkets.com/articles/2014/09/23/the_fda_should_be_in_ebola-mode_all_the_time_101288.html

- The Wikipedia article says the drug's been withdrawn from sale pending relabeling and re-targetting (at higher prices). Anyone know whether it's still available and in which countries? Thanks wiki-ny-2007 (talk) 15:22, 27 September 2014 (UTC)Reply

What dose and price applied to CLL ? What value of sales for CLL ? What dose and price is now applied to MS ? - Rod57 (talk) 12:18, 17 October 2016 (UTC)Reply

UK price for Lemtrada alemtuzumab 10 mg/mL, net price 1.2-mL vial = £7045.00[2] ~ £56,000 (for 5 + 3 infusions)[3]- Rod57 (talk) 12:29, 17 October 2016 (UTC)Reply

Hello fellow Wikipedians,

I have just modified one external link on Alemtuzumab. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:

• Added archive https://web.archive.org/web/20110714063804/http://www.campath.com/hcp/AboutCampath.html to http://www.campath.com/hcp/AboutCampath.html

When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.

This message was posted before February 2018. After February 2018, "External links modified" talk page sections are no longer generated or monitored by InternetArchiveBot. No special action is required regarding these talk page notices, other than regular verification using the archive tool instructions below. Editors have permission to delete these "External links modified" talk page sections if they want to de-clutter talk pages, but see the RfC before doing mass systematic removals. This message is updated dynamically through the template {{source check}} (last update: 5 June 2024).

• If you have discovered URLs which were erroneously considered dead by the bot, you can report them with this tool.
• If you found an error with any archives or the URLs themselves, you can fix them with this tool.

Cheers.—InternetArchiveBot (Report bug) 14:37, 30 June 2017 (UTC)Reply

article says "In MS it is generally only recommended if other treatments have not worked"

This was the case until a fiveish years ago, but there is a growing consensus that it should be first-line, because the earlier it and other 'highly effective-class' drugs are taken the greater the long-term benefits are.

The consensus doesn't seem to have been firmly established but might be an idea to add a clause to say

"In MS it is generally only recommended if other treatments have not worked, though numerous clinicians are arguing it should becomee a first-line therapy"

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501364/ 2A01:4B00:9D30:C000:D5F3:ED30:1712:1887 (talk) 08:50, 24 August 2023 (UTC)Reply